首页|Gold mineralized"hybrid nanozyme bomb"for NIR-Ⅱ triggered tumor effective permeation and cocktail therapy

Gold mineralized"hybrid nanozyme bomb"for NIR-Ⅱ triggered tumor effective permeation and cocktail therapy

扫码查看
原文链接
  • 万方数据
Lung cancer is one of the most common malignant tumors with the fastest increase in the incidence rate and mortality.Even after maximum tumor resection assistance with a radiotherapy and chemotherapy combination,the recurrence of non-small cell lung cancer is still inevitable.In addition,low targeting efficiency and poor permeability of drug delivery systems strongly affect the therapeutic efficiency of anti-cancer drugs on non-small cell lung cancer.Here we designed a gemcitabine(GEM)loaded arginine-glycine-aspartic acid-cysteine(RGDc)-modified gold mineralization"hybrid nanozyme bomb"(RGTG)to overcome those obstacles.RGDc modification improved the active targeting of liposomes to the tumor tissues with the second near-infrared(NIR-Ⅱ)-triggered gold-shell disruption and GEM release.The col-lapsed gold-shell particles with a smaller size could penetrate the tumor solid barrier and act as pho-tothermal therapy(PTT)agents to improve PTT therapy and starvation therapy via generating gluconic acid and reactive oxygen species(ROS).Moreover,the resting reversal effect of gold particles on tumor fibroblasts can achieve accelerating tumor penetration of gold particles and GEM.Compared to monother-apy,RGTG showed significant improvement in tumor inhibition,with a tumor volume reduction of 83％compared to the control group,which provides a promising tumor treatment platform for non-small cell lung cancer(NSCLC).

Gold mineralizedHybrid nanozyme bombStarvation therapyCocktail therapyNSCLC

Ji Liu、Dongsheng He、Tianjiao Hao、Yumin Hu、Yan Zhao、Zhen Li、Chang Liu、Daquan Chen、Qiyue Wang、Xiaofei Xin、Yan Shen

展开 >

Department of Pharmaceutics,State Key Laboratory of Nature Medicines,China Pharmaceutical University,Nanjing 210009,China

Wuxi Hequan Pharmaceutical Co.,Ltd.,Wuxi 214029,China

Beijing Xinghao Yingsheng Pharmaceutical Co.,Ltd.,Beijing 102609,China

School of Pharmacy,Yantai University,Yantai 264005,China

School of Pharmaceutical Science,Nanjing Tech University,Nanjing 211816,China

展开 >

2024

10.1016/j.cclet.2023.109296

中国化学快报(英文版)
中国化学会

中国化学快报(英文版)

CSTPCD
影响因子：0.771
ISSN：1001-8417
年,卷(期)：2024.35(9)